CORDIS
EU research results

CORDIS

English EN
BeTheCuRE

BeTheCuRE

Objective

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that will enable us and EFPIA partners to develop precise and eventually curative treatments to be used before a non-reversible destruction and function loss have occurred. The composition of the consortium include complementarities. Partners are involved to have large cohorts and biobank, to be excellent in understanding and modulating adaptive immunity, and to be able to take both these assets into clinical development of new therapeutics. The aim is to provide the basis for such development together with the EFPIA partners. All partners have a specific role in the development of specific technologies, mouse models, biobanks, systems for studying the adaptive immunity and drug development. Taken together the access for us and the EFPIA partners to this infrastructure and innovative projects will permit the development of new and innovative and ultimately curative therapies for early arthritis.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UCB BIOPHARMA SPRL

Address

Allee De La Recherche 60
1070 Brussels

Belgium

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Neil Gozzard (Dr)

Administrative Contact

Simon Dresse (Mr)

Participants (38)

Sort alphabetically

Sort by EU Contribution

Expand all

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 3 279 727

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 1 810 684

UNIVERSITAT ZURICH

Switzerland

EU Contribution

€ 1 008 920

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 600 769

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 601 846

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 1 122 895

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 852 328

Diakonhjemmet Hospital

Norway

EU Contribution

€ 92 226

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 864 761

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 592 841

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 743 191

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 415 024

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 277 960

CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER

France

EU Contribution

€ 367 518

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 366 269

REVMATOLOGICKY USTAV

Czechia

EU Contribution

€ 279 240

FONDAZIONE HUMANITAS PER LA RICERCA

Italy

EU Contribution

€ 609 993

BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING

Greece

EU Contribution

€ 852 394

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 544 792

Deutsches Rheuma-Forschungszentrum Berlin

Germany

EU Contribution

€ 377 625

TcLand Expression

France

EU Contribution

€ 80 113

BRISTOL-MYERS SQUIBB COMPANY CORP

United States

Janssen Biologics

Netherlands

ASTRAZENECA AB

Sweden

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

PFIZER LIMITED

United Kingdom

NOVO NORDISK A/S

Denmark

MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN

Germany

Phadia AB

Sweden

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 281 363

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 330 746

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 549 246

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 270 690

Arthrogen BV

Netherlands

BIOMEDCODE ELLAS ANONIMI ETERIA EPISTIMONIKIS KAI TEXNOLOGIKIS EREVNAS KAI EMBORIKIS EKMETALLEFSIS EPHARMOGON IATRIKIS

Greece

EU Contribution

€ 99 099

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

REDOXIS AB

Sweden

EU Contribution

€ 1 035

FIRALIS

France

EU Contribution

€ 89 577

Project information

Grant agreement ID: 115142

Status

Closed project

  • Start date

    1 April 2011

  • End date

    31 March 2017

Funded under:

FP7-JTI

  • Overall budget:

    € 38 071 092

  • EU contribution

    € 17 362 872

Coordinated by:

UCB BIOPHARMA SPRL

Belgium